AGENUS INC Other Nonoperating Income (Expense)
AGENUS INC (AGEN) reported Other Nonoperating Income (Expense) of $3.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-07
- AGENUS INC other nonoperating income (expense) for the quarter ending 2026-06-30 was $3.38M.
- AGENUS INC other nonoperating income (expense) for the quarter ending 2026-03-31 was $38.82M.
- AGENUS INC other nonoperating income (expense) for the quarter ending 2025-12-31 was -$8.99M.
- AGENUS INC other nonoperating income (expense) for the quarter ending 2025-09-30 was $81.63M, a 429510.53% increase year-over-year.
- AGENUS INC other nonoperating income (expense) for fiscal 2025 was $72.36M, a 1141.15% increase from fiscal 2024.
- AGENUS INC other nonoperating income (expense) for fiscal 2024 was $5.83M, a 15656.76% increase from fiscal 2023.
- AGENUS INC other nonoperating income (expense) for fiscal 2023 was $37.00K, a 99.65% decline from fiscal 2022.
- AGENUS INC other nonoperating income (expense) for fiscal 2022 was $10.63M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.38M 10-Q · filed 2026-08-07 | $42.20M 10-Q · filed 2026-08-07 | $33.21M derived: sum of 3 quarters · filed 2026-08-07 | $114.84M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $38.82M 10-Q · filed 2026-05-11 | $29.83M derived: sum of 2 quarters · filed 2026-05-11 | $111.46M derived: sum of 3 quarters · filed 2026-05-11 | $111.44M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$8.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $72.64M derived: sum of 2 quarters · filed 2026-03-16 | $72.62M derived: sum of 3 quarters · filed 2026-08-07 | $72.36M 10-K · filed 2026-03-16 |
| 2025-09-30 | $81.63M 10-Q · filed 2025-11-10 | $81.61M derived: sum of 2 quarters · filed 2026-08-07 | $81.35M 10-Q · filed 2025-11-10 | $81.13M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$12.00K 10-Q · filed 2026-08-07 | -$276.00K 10-Q · filed 2026-08-07 | -$500.00K derived: sum of 3 quarters · filed 2026-08-07 | -$481.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$264.00K 10-Q · filed 2026-05-11 | -$488.00K derived: sum of 2 quarters · filed 2026-05-11 | -$469.00K derived: sum of 3 quarters · filed 2026-05-11 | $6.67M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$205.00K derived: sum of 2 quarters · filed 2026-03-16 | $6.94M derived: sum of 3 quarters · filed 2026-03-16 | $5.83M 10-K · filed 2026-03-16 |
| 2024-09-30 | $19.00K 10-Q · filed 2025-11-10 | $7.16M derived: sum of 2 quarters · filed 2025-11-10 | $6.05M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $7.14M 10-Q · filed 2025-08-11 | $6.04M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$1.11M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $37.00K 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $10.63M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |